Citations

Clear

9383 citation(s) found for "Thomas, PS".

“Diabetic Mastopathy,” or Sclerosing Lymphocytic Lobulitis, Is Strongly Associated With Type 1 Diabetes
Kudva, Yogish C. , Reynolds, Carol, Powell, Claudia, Oberg, Ann L. , Crotty, Thomas B., O’Brien, Timothy

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 25 | Issue: 1 | Pages: 121-126

10.2337/diacare.25.1.121 | PMID 11772912 Get It

OBJECTIVE—To demonstrate the strong association of diabetic mastopathy or sclerosing lymphocytic lobulitis with type 1 diabetes mellitus by studying appropriate control groups and to describe risk factors and natural history of the disorder. RESEARCH DESIGN AND METHODS—This was a retrospective cross-sectional study of four groups of patients conducted at a setting tertiary care medical center. We examined benign breast biopsies (investigator masked to identity) from age-matched patients with types 1 and 2 diabetes, autoimmune thyroid disease, or none of the above disorders for sclerosing lymphocytic lobulitis. Several risk factors proposed for the disorder (age at diagnosis of benign breast disease, duration of diabetes, age at onset of diabetes, prevalence of retinopathy, neuropathy, nephropathy and cheiroarthropathy, glycemic control, parity, oral contraceptive use, menopausal status, or number of breast biopsies) were evaluated, and patients were contacted to describe the natural history of the disorder. RESULTS—Sclerosing lymphocytic lobulitis was identified in 69.7% of the subjects with type 1 diabetes and 1.8% of those with autoimmune thyroid disease diagnosed with benign breast disease at surgery. It did not occur in patients with type 2 diabetes with or without insulin treatment or in control subjects. Only retinopathy and peripheral neuropathy were associated with sclerosing lymphocytic lobulitis. Breast carcinoma or lymphoma did not occur subsequently in any type 1 diabetes patient with or without sclerosing lymphocytic lobulitis. CONCLUSIONS—Sclerosing lymphocytic lobulitis is strongly associated with type 1 diabetes. Retinopathy and neuropathy are associated with the disorder. The risk of malignancy is not increased.
Screening Mammogram Utilization in Women With Diabetes
Beckman, Thomas J. , Cuddihy, Robert , Scheitel, Sidna M., Naessens, James M. , Killian, Jill M. , Pankratz, V. Shane , Cuddihy, Robert M

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 24 | Issue: 12 | Pages: 2049-2053

10.2337/diacare.24.12.2049 | PMID 11723081 Get It

OBJECTIVE—To determine whether women with diabetes undergo fewer screening mammograms than matched control subjects.RESEARCH DESIGN AND METHODS—A total of 424 women with diabetes aged 50–75 years who received their primary care from general internists at a large Midwestern multispecialty group practice were retrospectively studied for frequency of mammography from August 1997 to January 2000. Two control subjects without diabetes (n = 845) were matched to each case by age, sex, provider, and date of visit. The main outcome measure was the percentage of subjects undergoing mammography 1 year before and 30 days after an index date, defined as the most recent health care visit after August 1997 and before January 2000.RESULTS—Analysis by conditional logistic regression demonstrated that women with diabetes had significantly lower rates of mammograms than control subjects (78.1 vs. 84.9%, respectively; odds ratio 0.63, P = 0.002). After adjusting for insurance status and race, women with diabetes continued to have significantly lower rates of mammography (odds ratio 0.70, P = 0.027).CONCLUSIONS—Women with diabetes were significantly less likely to undergo screening mammography than control subjects. Considering the increasing incidence of diabetes and the equal incidence of malignancy in women with and without diabetes, it would be beneficial to improve breast cancer screening in this population.
IL1RN VNTR Polymorphism in Ischemic Stroke
Worrall, Bradford B. , Brott, Thomas G. , Brown, Robert D., Brown, W. Mark , Rich, Stephen S. , Arepalli, Sampath, Vrièze, Fabienne Wavrant‐De, Duckworth, Jaime, Singleton, Andrew , Hardy, John , Meschia, James F. , Rich, Stephen S , Hardy, John

Mayo Clinic

Stroke | March 2, 2007 | Volume: 38 | Issue: 4 | Pages: 1189-1196

10.1161/01.str.0000260099.42744.b0 | PMID 17332449 Get It

Background and Purpose— Genetic factors influence risk for ischemic stroke and likely do so at multiple steps in the pathogenic process. Variants in genes related to inflammation contribute to risk of stroke. The purpose of this study was to confirm our earlier finding of an association between allele 2 of a variable number tandem repeat of the IL-1 receptor antagonist gene ( IL1RN ) and cerebrovascular disease. Methods— An association study of the variable number tandem repeat genotype with ischemic stroke and stroke subtypes was performed on samples from a North American study of affected sibling pairs concordant for ischemic stroke and 2 North American cohorts of prospectively ascertained ischemic stroke cases and unrelated controls. DNA analysis was performed on cases and controls, stratified by race. Results— After adjustment for age, sex, and stroke risk factors, the odds ratio for association of allele 2 and ischemic stroke was 2.80 (95% confidence interval, 1.29 to 6.11; P =0.03) for the white participants. The effect of allele 2 of IL1RN on stroke risk most closely fits a recessive genetic model ( P =0.009). For the smaller sample of nonwhite participants, the results were not significant. Conclusions— Allele 2 of IL1RN , present in nearly one-quarter of stroke patients, may contribute to genetic risk for ischemic stroke and confirm the previously identified association with cerebrovascular disease. These results are driven by the association in the white participants. Further exploration in a larger nonwhite sample is warranted.
Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival
Cerhan, James R. , Wang, Sophia , Maurer, Matthew J. , Ansell, Stephen M. , Geyer, Susan M. , Morton, Lindsay M. , Severson, Richard K., Rothman, Nathaniel , Lynch, Charles F. , Wacholder, Sholom, Hartge, Patricia, Cozen, Wendy , Davis, Scott , Chanock, Stephen Jacob , Habermann, Thomas M. , Maurer, Matthew , Cerhan, James R , Morton, Lindsay M , Wang, Sophia S

Mayo Clinic

Blood | February 28, 2007 | Volume: 109 | Issue: 12 | Pages: 5439-5446

10.1182/blood-2006-11-058040 | PMID 17327408 Get It

AbstractRecent gene-expression data have suggested that host immune genetic signatures may predict outcomes in patients with follicular lymphoma. We evaluated the hypothesis that germ line common variation in candidate immune genes is associated with survival. Cox models were used to estimate hazard ratios (HR) and corresponding 95% confidence intervals for individual SNPs after accounting for age, clinical, and other demographic factors. The median age at diagnosis of the 278 patients was 57 years, and 59 (21%) of the patients died during follow-up, with a median follow-up of 59 months (range, 27-78 months) for surviving patients. SNPs in IL8 (rs4073; HRTT = 2.14, 1.26-3.63), IL2 (rs2069762; HRGT/TT = 1.80, 1.06-3.05), IL12B (rs3212227; HRAC/CC = 1.83, 1.06-3.06), and IL1RN (rs454078; HRAA = 1.93, 1.11-3.34) were the most robust predictors of survival. A summary score of the number of deleterious genotypes from these genes was strongly associated with survival (P = .001). A risk score that combined the 4 SNPs with the clinical and demographic factors was even more strongly associated with survival (P < .001); the 5-year Kaplan-Meier survival estimates were 96% (93%-100%), 72% (62%-83%), and 58% (48%-72%) for groups at low, intermediate, and high risk, respectively. Common variation in host immune genes warrants further evaluation as a promising class of prognostic factors in follicular lymphoma.
Patient‐specific daily pretreatment setup protocol using electronic portal imaging for radiation therapy
Wittmer, Michael H., Pisansky, Thomas M. , Kruse, Jon J. , Herman, Michael

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 22, 2007 | Volume: 6 | Issue: 4 | Pages: 1-13

10.1120/jacmp.v6i4.1954 | PMID 16421496 Get It

The purpose of this study was to evaluate electronic portal imaging (EPI) as a means of identifying and correcting field displacement in patients with problematic external beam radiotherapy setups. Fourteen patients with problematic setups were identified for pretreatment daily EPI beam monitoring as part of a physician‐directed therapist intervention protocol. Pretreatment EPIs were used to realign fields as necessary to bring the setup within the physician‐prescribed tolerance level. For comparison, daily EPIs were available for 12 control patients who had no particular setup difficulties and for whom online beam realignment was not made. Anatomy‐matching software was used to measure setup variation along medial‐lateral, superior‐inferior, and anterior‐posterior axes. Online field realignment yielded a significant improvement when comparing initial and final setup variations. The mean standard deviation of setup displacement averaged over three axes was reduced from 6.4 mm to 3.1 mm after realignment. The final variation of protocol patients was comparable to that of control patients. In conclusion, EPI provided effective means to perform online beam realignment in a group of difficult‐to‐position patients. This procedure resulted in a reduction in setup displacement that was statistically significant, clinically relevant, and approached that of a more typical patient group.PACS number: 87.53.Oq
Measurement of Caval Blood Flow with MRI During Respiratory Maneuvers: Implications for Vascular Contrast Opacification on Pulmonary CT Angiographic Studies
Kuzo, Ronald S. , Pooley, Robert A. , Gerber, Thomas C., Crook, Julia E. , Heckman, Michael G. , Kuzo, Ronald S

Mayo Clinic

American Journal of Roentgenology | February 20, 2007 | Volume: 188 | Issue: 3 | Pages: 839-842

10.2214/ajr.06.5035 | PMID 17312076 Get It

Rickets: Vitamin D and Calcium Deficiency
Thacher, Tom D. , Pettifor, John Μ. , Fischer, Philip R. , Pettifor, John M , Thacher, Thomas D

Mayo Clinic

Journal of Bone and Mineral Research | February 12, 2007 | Volume: 22 | Issue: 4 | Pages: 638-638

10.1359/jbmr.070118 | PMID 17362137 Get It

Lack of aggregation of ischemic stroke subtypes within affected sibling pairs
Wiklund, Per-Gunnar, Brown, W. Mark , Brott, Thomas G. , Brown, Robert D., Nilsson-Ardnor, Sofie, Hardy, John , Kissela, Brett , Singleton, Andrew , Holmberg, Dan , Rich, Stephen S. , Stegmayr, Bernd Georg , Meschia, James F. , Rich, Stephen S , Hardy, John

Mayo Clinic

Neurology | February 5, 2007 | Volume: 68 | Issue: 6 | Pages: 427-431

10.1212/01.wnl.0000252955.17126.6a | PMID 17283317 Get It

Randomized Phase II Trial of Paclitaxel Plus Carboplatin or Gemcitabine Plus Cisplatin in Eastern Cooperative Oncology Group Performance Status 2 Non–Small-Cell Lung Cancer Patients: ECOG 1599
Langer, Corey J. , Li, Sigui, Schiller, Joan H. , Tester, William , Rapoport, Bernardo L. , Johnson, David H.

Mayo Clinic

Journal of Clinical Oncology | February 2, 2007 | Volume: 25 | Issue: 4 | Pages: 418-423

10.1200/jco.2005.04.9452 | PMID 17264337 Get It

Purpose Appropriate therapy for Eastern Cooperative Oncology Group (ECOG) performance status (PS) -2 patients with advanced non–small-cell lung cancer (NSCLC) remains challenging. PS-2 patients on ECOG 1594 had a median survival (MS) of only 4.1 months and 1-year overall survival (OS) of 19%. Three percent had grade 5 toxicity. Patients and Methods ECOG 1599, the first PS 2–specific, US cooperative group trial for treatment-naïve advanced NSCLC, randomly assigned patients to dose-attenuated carboplatin/paclitaxel (the least toxic regimen in ECOG 1594) or gemcitabine/cisplatin (which yielded an MS of 7.9 months in PS-2 patients). Patients received either carboplatin (area under the concentration-time curve, 6) and paclitaxel 200 mg/m2 every 3 weeks (CbP) or gemcitabine 1 g/m2 days 1 and 8 and cisplatin 60 mg/m2 day 1 every 3 weeks (CG). Results One hundred three patients were enrolled; 100 proved eligible. Median age was 66 years; 46% had at least 5% weight loss; 88% had stage IV or recurrent disease. Median number of cycles administered was three per arm. CbP featured more grade 3 neutropathy (10% v 0%) and more grade ≥ 3 neutropenia (59% v 33%), whereas CG yielded more grade ≥ 3 thrombocytopenia (33% v 14%), more grade ≥ 3 fatigue (22% v 14%), and more grade ≥ 1 creatinine elevations (43% v 6%). One grade 5 toxicity, confined to the CbP arm, occurred. Response rate, time to progression, MS, and 1-year OS rates for CG and CbP, were 23%, 4.8 months, 6.9 months, and 25%, and 14%, 4.2 months, 6.2 months, and 19%, respectively. Conclusion Platinum-based combination chemotherapy for PS-2 patients with NSCLC is feasible with acceptable toxicity, but survival in these patients remains inferior to that of PS-0 to -1 patients.
Novel Approaches to Stroke Prevention in Atrial Fibrillation
Brott, Thomas G.

Mayo Clinic

Stroke | February 2, 2007 | Volume: 38 | Issue: 2 | Pages: 614-614

10.1161/01.str.0000255982.72103.7f | PMID 17261700 Get It